Mutual Advisors LLC Purchases 50 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Mutual Advisors LLC boosted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 6.0% during the second quarter, HoldingsChannel reports. The fund owned 888 shares of the biopharmaceutical company’s stock after buying an additional 50 shares during the quarter. Mutual Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $500,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Nuveen LLC bought a new stake in shares of Regeneron Pharmaceuticals during the first quarter valued at about $343,764,000. Pacer Advisors Inc. increased its position in shares of Regeneron Pharmaceuticals by 2,296.9% during the first quarter. Pacer Advisors Inc. now owns 407,370 shares of the biopharmaceutical company’s stock valued at $258,366,000 after buying an additional 390,374 shares during the period. Goldman Sachs Group Inc. increased its position in shares of Regeneron Pharmaceuticals by 18.0% during the first quarter. Goldman Sachs Group Inc. now owns 1,143,093 shares of the biopharmaceutical company’s stock valued at $724,984,000 after buying an additional 174,056 shares during the period. Vanguard Group Inc. increased its position in shares of Regeneron Pharmaceuticals by 1.3% during the first quarter. Vanguard Group Inc. now owns 9,407,891 shares of the biopharmaceutical company’s stock valued at $5,966,767,000 after buying an additional 121,545 shares during the period. Finally, Price T Rowe Associates Inc. MD increased its position in shares of Regeneron Pharmaceuticals by 4.3% during the first quarter. Price T Rowe Associates Inc. MD now owns 2,175,026 shares of the biopharmaceutical company’s stock valued at $1,379,467,000 after buying an additional 89,579 shares during the period. 83.31% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on REGN. Citigroup upped their price target on Regeneron Pharmaceuticals from $650.00 to $660.00 and gave the company a “buy” rating in a research report on Monday, October 13th. UBS Group reiterated a “neutral” rating on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st. Rothschild & Co Redburn began coverage on Regeneron Pharmaceuticals in a research report on Thursday, August 14th. They set a “buy” rating and a $890.00 price target on the stock. Raymond James Financial upgraded Regeneron Pharmaceuticals to a “moderate buy” rating in a research report on Tuesday, September 2nd. Finally, Truist Financial decreased their price target on Regeneron Pharmaceuticals from $940.00 to $812.00 and set a “buy” rating on the stock in a research report on Monday, August 11th. Three equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $817.88.

Regeneron Pharmaceuticals Stock Up 1.6%

Shares of NASDAQ REGN opened at $578.05 on Monday. Regeneron Pharmaceuticals, Inc. has a 12 month low of $476.49 and a 12 month high of $1,002.69. The company has a current ratio of 4.60, a quick ratio of 3.72 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $61.27 billion, a price-to-earnings ratio of 14.57, a PEG ratio of 1.80 and a beta of 0.31. The business has a 50-day moving average of $574.64 and a 200-day moving average of $562.12.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, topping the consensus estimate of $8.43 by $4.46. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The company had revenue of $3.68 billion during the quarter, compared to analyst estimates of $3.30 billion. During the same quarter in the previous year, the firm earned $11.56 earnings per share. Regeneron Pharmaceuticals’s revenue was up 3.6% on a year-over-year basis. Sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th were paid a $0.88 dividend. The ex-dividend date of this dividend was Monday, August 18th. This represents a $3.52 annualized dividend and a yield of 0.6%. Regeneron Pharmaceuticals’s dividend payout ratio is currently 8.87%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.